References
- Królewski AS, Warram JH, Christlieb AR. Onset, course, complications, and prognosis of diabetes mellitus. In: Marble A, Krall LP, Bradley RF, et al, eds. Joslin's diabetes mellitus. 12th ed. Philadelphia: Lea & Febiger, 1985: 251–77
- Steingart RM, Packer M, Hamm P, et al. Sex differences in the management of coronary artery disease. N Engl J Med 1991;325(4):226–30
- Sprafka JM, Burke GL, Folsom AR, et al. Trends in prevalence of diabetes mellitus in patients with myocardial infarction and effect of diabetes on survival: the Minnesota Heart Survey. Diabetes Care 1991;14(7):537–43
- Stern MP, Patterson JK, Haffner SM, et al. Lack of awareness and treatment of hyperlipidemia in type II diabetes in a community survey. JAMA 1989;262(3):360–4
- Fontbonne A, Eschwège E, Cambien F, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989;32(5):300–4
- Schwartz CJ, Valente AJ, Sprague EA, et al. Pathogenesis of the atherosclerotic lesion: implications for diabetes mellitus. Diabetes Care 1992;15(9):1156–67
- American Diabetes Association. Nutritional recommendations and principles for individuals with diabetes mellitus: 1986. Diabetes Care 1987;10(1):126–32
- Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and Captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321(13):868–73
- Suarez L, Barrett-Connor E. Interaction between cigarette smoking and diabetes mellitus in the prediction of death attributed to cardiovascular disease. Am J Epidemiol 1984;120(5):670–5
- Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990;322(4):213–7
- Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990; 13(2):153–69
- Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990; 264(6):723–6
- Vinik AI, Colwell JA. Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Diabetes Care 1993;16(1):37–44
- Lahdenperä S, Tllly-Kiesi M, Vuorinen-Markkola H, et al. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care 1993;16(4):584–92
- Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317(20): 1237–45
- Koskinen P, Mänttäri M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992;15(7):820–5
- Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318(2): 81–6
- The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988;148(1):36–69
- American Diabetes Association. Detection and management of lipid disorders in diabetes. Diabetes Care 1993;16(5):828–34
- Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323(19): 1289–98